These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20140106)

  • 1. Warfarin pharmacogenomics.
    Li J; Wang S; Barone J; Malone B
    P T; 2009 Aug; 34(8):422-7. PubMed ID: 20140106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
    Stehle S; Kirchheiner J; Lazar A; Fuhr U
    Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics aspects of oral anticoagulants therapy.
    Militaru FC; Vesa SC; Pop TR; Buzoianu AD
    J Med Life; 2015; 8(2):171-5. PubMed ID: 25866574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves.
    Chung JE; Chang BC; Lee KE; Kim JH; Gwak HS
    Eur J Clin Pharmacol; 2015 Oct; 71(10):1229-36. PubMed ID: 26257249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.
    Bedewy AML; Sheweita SA; Mostafa MH; Kandil LS
    Indian J Hematol Blood Transfus; 2018 Apr; 34(2):328-336. PubMed ID: 29622878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin pharmacogenomics.
    Cavallari LH; Limdi NA
    Curr Opin Mol Ther; 2009 Jun; 11(3):243-51. PubMed ID: 19479657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.
    Aomori T; Obayashi K; Fujita Y; Araki T; Nakamura K; Nakamura T; Kurabayashi M; Yamamoto K
    Pharmazie; 2011 Mar; 66(3):222-5. PubMed ID: 21553655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
    Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
    J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing.
    Ruaño G; Thompson PD; Villagra D; Bower B; Kocherla M; Yazdanpanah G; Seip RL; Windemuth A; White CM; Duconge J; Holford TR; Wu AH
    Per Med; 2008 May; 5(3):225-232. PubMed ID: 29783498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population.
    Jia L; Wang Z; Men J; Cai H; Wei M
    Ther Clin Risk Manag; 2017; 13():421-425. PubMed ID: 28408837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of target genes across the warfarin pharmacological pathway.
    Lal S; Jada SR; Xiang X; Lim WT; Lee EJ; Chowbay B
    Clin Pharmacokinet; 2006; 45(12):1189-200. PubMed ID: 17112295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.
    Siguret V; Pautas E; Gouin-Thibault I
    Vitam Horm; 2008; 78():247-64. PubMed ID: 18374198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.
    Loebstein R; Vecsler M; Kurnik D; Austerweil N; Gak E; Halkin H; Almog S
    Clin Pharmacol Ther; 2005 May; 77(5):365-72. PubMed ID: 15900282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
    Yin T; Miyata T
    Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients.
    Jiang NX; Ge JW; Xian YQ; Huang SY; Li YS
    Biomed Rep; 2016 Apr; 4(4):453-458. PubMed ID: 27073631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.
    Oner Ozgon G; Langaee TY; Feng H; Buyru N; Ulutin T; Hatemi AC; Siva A; Saip S; Johnson JA
    Eur J Clin Pharmacol; 2008 Sep; 64(9):889-94. PubMed ID: 18542936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.